{
    "clinical_study": {
        "@rank": "158202", 
        "arm_group": [
            {
                "arm_group_label": "AZD1979", 
                "arm_group_type": "Experimental", 
                "description": "Single ascending doses of oral solution AZD1979"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo to match single ascending doses of oral solution AZD1979"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a first time in human study to assess the safety and tolerability of AZD1979\n      following oral administration of single ascending doses in healthy male volunteers.\n      Pharmacokinetics (what the body does to the drug) parameters will also be assessed as\n      secondary objectives."
        }, 
        "brief_title": "A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Subjects", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of signed and dated, written informed consent prior to any study specific\n             procedures\n\n          -  Healthy male volunteer aged 18 to 50 years\n\n          -  Have a BMI between 18 and 30 kg/m2, inclusive, and weigh at least 50 kg and no more\n             than 100 kg, inclusive\n\n        Exclusion Criteria:\n\n          -  History of any clinically important disease or disorder which, in the opinion of the\n             Investigator, may either put the volunteer at risk because of participation in the\n             study, or influence the results or the volunteer's ability to participate in the\n             study\n\n          -  History or presence of gastrointestinal, hepatic, or renal disease or any other\n             condition known to interfere with absorption, distribution, metabolism, or excretion\n             of drugs\n\n          -  Any clinically important illness, medical/surgical procedure, or trauma within 4\n             weeks of the first administration of IP\n\n          -  Any clinically important abnormalities in clinical chemistry, endocrine hormones,\n             hematology, or urinalysis results as judged by the Investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072993", 
            "org_study_id": "D3930C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": "AZD1979", 
                "description": "Single dose, oral solution administration", 
                "intervention_name": "AZD1979", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Single dose, oral solution administration", 
                "intervention_name": "Placebo to match", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Phase I, healthy, pharmacokinetics", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Single-center, Single-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral AZD1979 After Single-ascending Doses in Healthy Male Volunteers", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Quintiles Drug Research Unit Call Center, 0800 634 1132"
        }, 
        "overall_official": {
            "affiliation": "Quintiles 6700 W 115th Street, Overland Park, KS USA", 
            "last_name": "Eleanor Lisbon, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety variables in terms of: Adverse events, clinical laboratory variables, vital signs, electrocardiograms and telemetry, physical examinations, and assessments of anxiety and mood", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 62 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072993"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Pharmacokinetics of AZD1979 assessed by means of plasma concentration analyses", 
            "safety_issue": "No", 
            "time_frame": "up to 48 hours post dose"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}